PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 738 participants.

Also called NCT04089059

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose diagnostic
Phase
Not applicable
Enrolled
  • 738 participants (enrolled count) (from the registry)
Sponsor
Endotronix, Inc. (from the registry)
Registry
  • NCT NCT04089059
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Ireland (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04089059. Allocation not applicable; no masking; primary purpose diagnostic. Start 2020-01-10 (actual); primary completion 2028-04 (anticipated). Results posted on 2025-03-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROACTIVE-HF IDE Trial Heart Failure NYHA Class III
Acronym
PROACTIVE-HF
Condition
Heart Failure NYHA Class III
Intervention (Device)
Cordella™ Pulmonary Artery Sensor System
Lead sponsor
Endotronix, Inc. (class: industry)

Record details

Record id
cardio:ct-nct04089059
Content hash
a2f9720a859dddce98612cbd8fdf41a5874c904601a73944c520b55fae9f3d30